PWM
DNTH icon

Palumbo Wealth Management’s Dianthus Therapeutics DNTH Stock Holding History

Palumbo Wealth Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
3,103
-7,257
-70% -$634K 0.06% 189
2026
Q1 		$869K Sell
10,360
-4,607
-31% -$267K 0.21% 80
2025
Q4 		$617K Buy
14,967
+8,317
+125% +$322K 0.15% 109
2025
Q3 		$262K Buy
+6,650
New +$170K 0.08% 151

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Palumbo Wealth Management's DNTH Position: Q2 2026 in Review

Palumbo Wealth Management reduced its Dianthus Therapeutics (DNTH) stake by 70% in Q2 2026, selling an estimated $634K and leaving 3,103 shares worth $302K. The position accounts for 0.06% of the portfolio, ranked #189.

Palumbo Wealth Management first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. The position peaked at $869K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Palumbo Wealth Management held 3,103 shares of Dianthus Therapeutics worth $302K as of Q2 2026.
  • Palumbo Wealth Management sold 7,257 Dianthus Therapeutics shares in Q2 2026, an estimated $634K.
  • Dianthus Therapeutics made up 0.06% of Palumbo Wealth Management's portfolio in Q2 2026, its #189 holding.
  • Palumbo Wealth Management first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Palumbo Wealth Management's Dianthus Therapeutics position peaked at $869K in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.